Streetbeat News

Products Services

SNAP

Snap is releasing a new version of its AR development tool, Lens Studio 5.0 Beta, which includes increased productivity and new AI capabilities. The company has partnered with OpenAI to offer a ChatGPT Remote API, allowing developers to create new types of learning, conversational, and creative experiences for Snapchat users. The new tool also supports version control tools like Git, enabling multiple developers to work on projects simultaneously. Snap also announced that there are now 330,000 developers building on its AR platform who have created nearly 3.5 million Lenses.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:22 pm

AYRWF

RWBYF

TLRY

AYR Wellness, Inc. (OTC:AYRWF) has introduced Kiva Confections' Camino Soft Chews to its Florida dispensaries, following a three-year licensing agreement. Red White & Bloom Brands Inc. (CSE:RWB) (OTC:RWBYF) is entering Ohio's cannabis market through a licensing arrangement. Tilray Brands, Inc. (NASDAQ:TLRY) has launched a holiday campaign for its Canadian cannabis brand, Good Supply. Surfside Solutions Inc. is expanding its Commerce Media to reach more cannabis brands and retailers in the U.S. and Canada.

Portfolio Pulse from Nicolás Jose Rodriguez

November 09, 2023 | 6:21 pm

IKNA

Ikena Oncology Inc (NASDAQ:IKNA) shared initial data from its ongoing Phase 1 trial of IK-930, a potent Hippo-pathway inhibitor used in cancer treatment. The company reported stable disease in all seven patients with epithelioid hemangioendothelioma (EHE) treated with IK-930. Three of these patients experienced tumor shrinkage. A combination cohort for IK-930 and osimertinib in patients with EGFR-mutant non-small cell lung cancer is planned for 2024. Despite these developments, IKNA shares are down 64.90% at $1.45.

Portfolio Pulse from Vandana Singh

November 09, 2023 | 6:20 pm

C

GS

JPM

MS

JP Morgan Chase & Co is actively working with U.S. regulators to implement generative AI in banking. The bank is educating regulators on building and controlling AI models, including potential risks. Current pilot projects include AI-generated earnings summaries and an AI-powered helpdesk. The bank is also trademarking potential AI products like IndexGPT and developing tools to analyze Federal Reserve communications for trading insights.

Portfolio Pulse from Anusuya Lahiri

November 09, 2023 | 6:08 pm

PSNY

Polestar, an electric vehicle maker, is partnering with Israeli startup StoreDot to demonstrate a high-speed battery charging technology. The technology, which can add 100 miles of range in just five minutes, will be piloted in a prototype Polestar 5 performance sedan next year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:04 pm

IONS

Ionis Pharmaceuticals has announced positive results from a two-year Phase 2 open-label extension study of its investigational drug, donidalorsen, for patients with hereditary angioedema (HAE). The study showed a sustained reduction in HAE attacks and improved quality of life for patients. Donidalorsen recently received orphan drug designation in the U.S. and is expected to report Phase 3 results in H1 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:45 pm

SOLUSD

Matthew Sigel, a digital asset strategist at VanEck, will share his crypto outlook at Benzinga's Future of Digital Assets conference. Sigel's research includes Bitcoin, smart contract platforms, and emerging market crypto. He recently co-wrote a report on Solana (CRYPTO: SOL), predicting $8 billion in revenues for Solana token holders by 2030. He also noted Solana's 340% surge in 2023, outperforming Bitcoin's 114% rise.

Portfolio Pulse from Stjepan Kalinic

November 09, 2023 | 5:44 pm

ATRA

Atara Biotherapeutics announced that its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis did not meet the primary endpoint of confirmed disability improvement. Following this announcement, multiple firms downgraded the stock.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:37 pm

LLY

Eli Lilly's shares are trading lower despite the FDA approval of Zepbound for chronic weight management. The stock had gained on Wednesday following the approval.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:29 pm

NVDA

NVIDIA is reportedly planning to introduce three new AI chips for the Chinese market, which has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:05 pm